BRAF and melanoma: Although the combination of BRAF plus MEK inhibition and NIVO plus IPI immune checkpoint inhibition is more commonly used today than VEM or IPI monotherapy to treat advanced melanoma, this study shows that IPI has efficacy after treatment with VEM in patients with BRAF-mutated melanoma and that tumors remain sensitive to VEM re-treatment after progressing on IPI.